Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) announces the publication of its 2015 Annual Report for the year ended December 31, 2015. The filing, dated March 17, 2016, serves as a notification to the SEC and UK Listing Authority regarding the availability of the Annual Report, Annual Summary, and the 2016 Notice of Annual General Meeting. The document primarily focuses on risk disclosures, dividend schedules, and corporate governance rather than presenting new financial performance data, which was previously released in an unaudited preliminary results announcement on February 3, 2016.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity for the 2015 period. These figures are referenced as being contained within the 2015 Annual Report and the preliminary results announcement from February 2016, which are not included in this text. The only specific financial data points provided in this document relate to historical settlements and dividend dates:
- Historical Settlements: GSK paid $3 billion (£1.9 billion) in 2012 to resolve US government investigations and RMB 3 billion (£301 million) in 2014 to resolve a China government investigation.
- Dividend Schedule: The filing outlines ex-dividend and payment dates for Q4 2015 (including a special dividend) and the four quarters of 2016.
Material Changes and Strategic Context
While specific comparative financial metrics are absent, the filing highlights several material strategic and operational changes:
- Novartis Integration: The company is integrating businesses acquired from Novartis, which has accelerated transformation efforts in Pharmaceuticals, Vaccines, and Consumer Healthcare.
- Patent Expirations: The US patent for the Advair Diskus device is set to expire in August 2016, creating uncertainty regarding the timing and impact of generic entry for Seretide/Advair, a key revenue driver.
- Compensation Model Shift: In 2015, GSK globally implemented changes to sales professional compensation, eliminating rewards based on sales or market share in favor of rewards based on the quality of interactions with healthcare professionals.
- Regulatory Environment: The company notes ongoing extra-territorial anti-bribery and corruption (ABAC) investigations by US and UK authorities and increased global scrutiny on tax reform (OECD BEPS project).
- Legal and Regulatory Risks: Significant exposure to product liability litigation, patent challenges, and government investigations regarding sales and marketing practices. The company notes that litigation outcomes are inherently unpredictable.
- Intellectual Property: Risks associated with patent expirations and compulsory licensing in developing markets, which could limit sales growth and margins.
- Operational Risks: Potential for supply chain disruptions, product recalls due to quality failures, and data integrity issues in research.
- Geopolitical Risks: The company is evaluating the implications of a potential UK exit from the European Union (Brexit), though it currently does not anticipate a material adverse long-term impact.
- Information Security: Recent indictments of employees for theft of research information are noted, though management does not believe this has had a material impact on R&D or ongoing business.
- Verify the full 2015 Annual Report and February 3, 2016 preliminary results announcement for specific revenue, profit, and cash flow figures not included in this text.
- Review Note 45 ('Legal proceedings') in the Annual Report for detailed status updates on unresolved disputes, product liability lawsuits, and government investigations.
- Assess the timeline and potential financial impact of the August 2016 patent expiration for the Advair Diskus device and subsequent generic competition.
- Monitor the progress of the integration of Novartis-acquired businesses and the effectiveness of the new sales compensation model.
- Track developments in US and UK anti-bribery investigations and global tax reform initiatives (BEPS) that could affect the effective tax rate.
Guidance, Outlook, Risks, and Contingencies
The filing includes a comprehensive cautionary statement regarding forward-looking statements and details principal risks that could materially affect future results: